for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi SA

SASY.PA

Latest Trade

87.38EUR

Change

-0.10(-0.11%)

Volume

139,911

Today's Range

87.00

 - 

87.91

52 Week Range

67.65

 - 

95.82

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
87.48
Open
87.14
Volume
139,911
3M AVG Volume
53.08
Today's High
87.91
Today's Low
87.00
52 Week High
95.82
52 Week Low
67.65
Shares Out (MIL)
1,253.60
Market Cap (MIL)
110,131.80
Forward P/E
14.92
Dividend (Yield %)
3.60

Next Event

Sanofi SA at Morgan Stanley Global Healthcare Conference (Virtual)

Latest Developments

More

GSK says Sanofi, Co In Advanced Discussions With EU To Supply Up To 300 Mln Doses Of Covid-19 Vaccine

Sanofi And GSK: Collaborative Effort With U.S. Government To Accelerate Development Of COVID-19 Vaccine

Sanofi, GSK Selected For Operation Warp Speed To Supply U.S. Government With 100 Mln Doses Of Covid-19 Vaccine​

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Industry

Biotechnology & Drugs

Contact Info

54 rue la Boetie

75008

France

+33.1.53774000

https://www.sanofi.com/

Executive Leadership

Serge Weinberg

Independent Chairman of the Board

Paul Hudson

Chief Executive Officer, Member of the Executive Committee, Director

Jean-Baptiste Chasseloup de Chatillon

Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Karen Linehan

Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee

Caroline Luscombe

Executive Vice President of Human Resources, Member of the Executive Committee

Key Stats

2.00 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

35.1K

2018

34.5K

2019

36.1K

2020(E)

37.4K
EPS (EUR)

2017

5.540

2018

5.470

2019

5.990

2020(E)

5.904
Price To Earnings (TTM)
9.88
Price To Sales (TTM)
2.92
Price To Book (MRQ)
1.73
Price To Cash Flow (TTM)
8.74
Total Debt To Equity (MRQ)
39.42
LT Debt To Equity (MRQ)
33.77
Return on Investment (TTM)
11.36
Return on Equity (TTM)
9.44

Latest News

Latest News

U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers' testing and manufacturing, the companies said on Friday.

U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.

Sanofi, Glaxo advance talks to supply up to 300 million COVID-19 vaccine doses to Europe: companies

Sanofi SA <SASY.PA> and GlaxoSmithKline Plc <GSK.L> on Friday said they are in advanced discussions with the European Commission to supply up to 300 million doses of the drugmakers's experimental COVID-19 vaccine.

EU in talks to secure Sanofi deal for coronavirus vaccine

Sanofi SA and GlaxoSmithKline Plc on Friday said they are in advanced discussions to supply up to 300 million doses of an experimental COVID-19 vaccine for the 27-country European Union.

EU wraps up Sanofi talks aimed at securing coronavirus vaccine

The European Union's executive on Friday wrapped up talks with French drugmaker Sanofi aimed at securing its COVID-19 vaccine for the 27-country EU bloc.

BRIEF-Sanofi, GSK Selected For Operation Warp Speed To Supply U.S. Government With 100 Mln Doses Of Covid-19 Vaccine​

* SANOFI, GSK SELECTED FOR OPERATION WARP SPEED TO SUPPLY U.S. GOVERNMENT WITH 100 MILLION DOSES OF COVID-19 VACCINE

U.S. to pay $2.1 bln to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.

Sanofi lifts earnings view as Regeneron stake sale boosts second quarter

Sanofi <SASY.PA> raised its 2020 earnings forecast on Wednesday after its second-quarter results were boosted by cost cuts and the sale of most of its 20.6% stake in U.S. company Regeneron <REGN.O>, although revenue was hit by the coronavirus crisis.

Britain secures 60 million doses of Sanofi/GSK coronavirus vaccine

Britain has signed a deal for up to 60 million doses of a potential coronavirus vaccine being developed by Sanofi and GlaxoSmithKline (GSK), it said on Wednesday, its latest such arrangement as the race to tame the pandemic heats up.

Sanofi, GSK to supply up to 60 million doses of COVID-19 vaccine to UK

Sanofi <SASY.PA> and GSK <GSK.L> said they had reached an agreement with Britain to supply it with up to 60 million doses of a potential COVID-19 vaccine, and that discussions with other governments were ongoing.

BRIEF-Sanofi, GSK Agree With UK Government To Supply Up To 60 Mln Doses Of COVID-19 Vaccine

* SANOFI AND GSK AGREE WITH THE UK GOVERNMENT TO SUPPLY UP TO 60 MILLION DOSES OF COVID-19 VACCINE

Britain signs supply deal for 60 mln doses of Sanofi/GSK COVID-19 vaccine

Britain on Wednesday said it had signed a supply deal for up to 60 million doses of a possible COVID-19 vaccine being developed by Sanofi and GlaxoSmithKline, the fourth such deal it has struck.

Sanofi forges ahead with active ingredients spin-off-sources

Sanofi is starting preparations for a stock market listing of its active ingredients business as the French drugmaker pushes ahead with a strategy focusing on its more profitable businesses, sources told Reuters.

Macron says France will be among first to get Sanofi vaccine

French President Emmanuel Macron said on Tuesday France would be among the first countries to get access to a potential vaccine being developed by French drugmaker Sanofi.

BRIEF-Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients

* KYMERA THERAPEUTICS AND SANOFI ENTER INTO STRATEGIC PARTNERSHIP TO ADVANCE NOVEL PROTEIN DEGRADER THERAPIES TO PATIENTS

BRIEF-Sanofi Canada Says Sarclisa Available In Canada For Patients With Relapsed, Refractory Multiple Myeloma

* SANOFI CANADA - SARCLISA (ISATUXIMAB FOR INJECTION) AVAILABLE IN CANADA FOR PATIENTS WITH RELAPSED, REFRACTORY MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

BRIEF-Evotec Acquires Site From Sanofi, No Financial Terms Disclosed

* EVOTEC ACQUIRES SITE FROM SANOFI AND SECURES CAPACITY FOR LONG-TERM GROWTH

BRIEF-Kiadis Licenses Pre-Clinical K-NK-Cell Programmes To Sanofi

* KIADIS LICENSES PREVIOUSLY UNDISCLOSED PRE-CLINICAL K-NK-CELL PROGRAMS TO SANOFI, WITH TOTAL POTENTIAL DEAL VALUE OF €875 MILLION, PLUS ROYALTIES

Britain nears $625 million Sanofi/GSK COVID-19 vaccine deal - report

Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-19 vaccine, the Sunday Times reported.

Britain nears 500 million stg supply deal for Sanofi/GSK COVID-19 vaccine - Sunday Times

Britain is close to agreeing a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of their potential COVID-19 vaccine, the Sunday Times reported.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up